Key result
Stepwise lipid-lowering therapy with statins, ezetimibe, PCSK9 inhibitors, or icosapent ethyl cuts ASCVD risk in T2D.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is associated with increased risk for atherosclerotic cardiovascular disease (ASCVD) which is partly related to atherogenic dyslipidemia with raised triglycerides, reduced high-density lipoprotein cholesterol levels, and accompanying lipid changes. Treatment of this dyslipidemia is regarded as a priority to reduce the ASCVD risk in T2DM. AREAS COVERED: This article reviews the relevant studies and guidelines from the publications related to this area. EXPERT OPINION: Lifestyle modification should always be encouraged, and statin treatment is indicated in most patients with T2DM based on the outcome of randomized controlled trials. If LDL-C goals are not achieved, first, ezetimibe and subsequently proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors should be added. Patients with T2DM derive greater benefits from ezetimibe and PCSK9 inhibitors due to their higher absolute ASCVD risk compared to patients without T2DM. If triglyceride levels remain elevated, a high dose of eicosapentaenoic acid ethyl ester should be added. Fibrates should be used for severe hypertriglyceridemia to prevent acute pancreatitis. Novel treatments including pemafibrate and inclisiran are undergoing cardiovascular outcome trials, and RNA-based therapies may help to target residual hypertriglyceridemia and high lipoprotein(a) with the long acting treatments offering potential improved adherence to therapy.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2021) conducted a review in Dyslipidemia in Type 2 diabetes mellitus. Lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors, icosapent ethyl, fibrates, novel agents) was evaluated on Atherosclerotic cardiovascular disease (ASCVD) risk reduction. Statin therapy, combined sequentially with ezetimibe, PCSK9 inhibitors, or icosapent ethyl when lipid goals are unmet, is recommended to reduce ASCVD risk in patients with Type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: